OCV Partners — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
TORL BioTherapeuticsApr 2024
Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.
BiotechCulver City, US
Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)
PartnerChris Bostick· led
Co-investorsCowen Healthcare InvestmentsGoldman SachsPerceptive Xontogeny VentureVertex Ventures HC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.